Research That Could Shape Future EGFR-Mutated NSCLC Management

Luis Raez, MD, FACP, FCCP, and Alexander I. Spira MD, PhD, FACP, FASCO, highlight ongoing trials and emerging therapeutic strategies in EGFR-mutated non–small cell lung cancer. Spira discusses novel targeted agents, resistance-directed combinations, and approaches designed to improve CNS control and long-term outcomes. Raez emphasizes persistent unmet needs in the advanced-stage setting and the importance of biomarker-driven research to refine future standards of care.